MONDAY, March 23, 2020 — For men with intermediate- and high-risk prostate adenocarcinoma, 10-year outcomes are similar with conventionally fractionated intensity-modulated radiation therapy (C-IMRT) or moderate hypofractionated IMRT (H-IMRT),…
CONCLUSION: H-IMRT failed to demonstrate superiority compared with C-IMRT in long-term disease outcomes.
PMID: 32119599 [PubMed – as supplied by publisher]
AIM: To report toxicity and quality of life (QOL) outcomes from a randomised trial of prostate only versus whole pelvic radiotherapy in high risk, node negative prostate cancer.
MATERIALS/METHODS: Patients with localised prostate adenocarcinoma and nodal involvement risk > 20%, were randomised to prostate only (PORT, 68 Gy/25# to prostate) and whole pelvis (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis) arms with stratification for TURP, Gleason score, baseline PSA, and type of androgen deprivation therapy (ADT). Image guided intensity modulated radiotherapy (IG-IMRT…
Conditions: Metastatic Prostate Adenocarcinoma; Prostate Adenocarcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Radiation: Intensity-Modulated Radiation Therapy; Radiation: Proton Beam Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: Mayo…
Three-dimensional conformal radiation therapy, intensity-modulated radiotherapy (IMRT), and volumetric-modulated arc radiotherapy (VMAT) are more effective curative treatment options for patients with localized adenocarcinoma of the prostate, compared with surgery [1 –2]. Gastrointestinal toxicity is the major treatment-related side effect in prostate cancer radiotherapy. The rates of acute and chronic grade (≥2) rectal toxicity increase by dose – increasing from 3 and 5%, to 20 and 21%, respectively [3–5].
ConclusionCombining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.
Condition: Stage II Prostate Adenocarcinoma Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT) Sponsors: NRG Oncology; National Cancer Institute (NCI) Not yet recruiting